# Travanti Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/travanti-pharma

- Industry: Biotechnology
- Headquarters: Mendota Heights, US
- Website: www.travantipharma.com
- Total disclosed funding: $7.5M
- Latest round: Series B (Jul 1, 2006)
- Investors on record: 2

## About

Travanti Pharma is a pharmaceutical company specializing in innovative drug delivery solutions, particularly through microneedle technology. Its focus is on enhancing the efficiency of vaccine and medication administration.Travanti Pharma operates in Mendota Heights, US, focusing on advanced drug delivery systems. The company was acquired by Teikoku Pharma USA in May 2009. Its founder has a background in the pharmaceutical industry, having previously founded other companies. Travanti Pharma has successfully closed 2 funding deals, including the most recent Series B round in which USD 7.50 mn was raised from investors Prolog Ventures and Spring Bay Companies, bringing its total funding to USD 7.50 mn.Travanti Pharma specializes in innovative microneedle technology, primarily offering the AdminPen™ pen-injector and AdminStamp devices that utilize the patented AdminPatch® microneedle array technology. The AdminPen™ is designed for painless delivery of vaccines, medical drugs, cosmetics, and supplements through a targeted area, aiming for FDA Class II medical device classification. The AdminStamp devices enhance topical formulation absorption, catering to both medical and cosmetic sectors and are anticipated to enter markets across North America, Europe, and Asia.Travanti Pharma generates revenue through sales of its microneedle devices, including AdminPen™ and AdminStamp, via partnerships with healthcare providers and retailers. Sales are structured for both B2B and direct-to-consumer models, with pricing consistent with industry standards for medical devices, ensuring a sustainable revenue stream as the products gain traction in various markets.Looking ahead, Travanti Pharma aims to launch upcoming products utilizing its microneedle technology, though specific release dates are not disclosed. The company is strategically planning to expand into additional markets across North America, Europe, and Asia. The recent funding from the Series B round is expected to support these initiatives, enhancing product development and marketing efforts.

## Funding rounds

- Series B, Jul 1, 2006, $7.5M — Prolog Ventures, Spring Bay Companies

## Investors

- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series B
- Spring Bay Companies (https://capitalatlas.ai/funds/spring-bay-companies) — Series B